Journal article
Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial
Marie Sinclair, Mathis Grossmann, Rudolf Hoermann, Peter W Angus, Paul J Gow
JOURNAL OF HEPATOLOGY | ELSEVIER | Published : 2016
Abstract
BACKGROUND & AIMS: Low testosterone and sarcopenia are common in men with cirrhosis and both are associated with increased mortality. Whether testosterone therapy in cirrhosis improves muscle mass and other outcomes is unknown. METHODS: We conducted a 12-month, double-blinded, placebo-controlled trial of intramuscular testosterone undecanoate in 101 men with established cirrhosis and low serum testosterone (total testosterone <12nmol/L or free testosterone <230pmol/L) in a single tertiary centre. Body composition was assessed using dual-energy X-ray absorptiometry at baseline, 6 and 12months. RESULTS: At study completion, appendicular lean mass was significant higher in testosterone-treated ..
View full abstractGrants
Awarded by NHMRC Career Development Fellowship
Funding Acknowledgements
The completion of this work was assisted by an Australian Postgraduate Award from the University of Melbourne and a Research Scholarship from Avant Mutual group awarded to MS. MG was supported by a NHMRC Career Development Fellowship (#1024139).Bayer Pharma AG (Berlin, Germany) provided study drug and financial support to conduct investigations, but had no role in trial design, data analysis, manuscript preparation or the decision to submit the manuscript for publication.